Patents by Inventor John A. Galloway

John A. Galloway has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glucagon-like insulinotropic peptides, compositions and methods
    Patent number: 7232879
    Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: June 19, 2007
    Assignee: Eli Lilly and Company
    Inventors: John A. Galloway, James A. Hoffmann
  • Glucagon-like insulinotropic peptides, compositions and methods
    Publication number: 20040127399
    Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.
    Type: Application
    Filed: January 30, 2004
    Publication date: July 1, 2004
    Inventors: John A. Galloway, James A. Hoffmann
  • Glucagon-like insulinotropic peptides, compositions and methods
    Patent number: 6703365
    Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.
    Type: Grant
    Filed: April 17, 2002
    Date of Patent: March 9, 2004
    Assignee: Eli Lilly and Company
    Inventors: John A. Galloway, James A. Hoffmann
  • Glucagon-like insulinotropic peptides, compositions and methods
    Publication number: 20020165342
    Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.
    Type: Application
    Filed: April 17, 2002
    Publication date: November 7, 2002
    Inventors: John A. Galloway, James A. Hoffmann
  • Glucagon-like insulinotropic peptides, compositions and methods
    Patent number: 6410513
    Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: June 25, 2002
    Assignee: Eli Lilly and Company
    Inventors: John A. Galloway, James A. Hoffman
  • Glucagon-like insulinotropic peptides, compositions and methods
    Patent number: 6388053
    Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.
    Type: Grant
    Filed: October 12, 2001
    Date of Patent: May 14, 2002
    Assignee: Eli Lilly and Company
    Inventors: John A. Galloway, James A. Hoffmann
  • Glucagon-like insulinotropic peptides compositions and methods
    Patent number: 6133235
    Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.
    Type: Grant
    Filed: July 6, 1999
    Date of Patent: October 17, 2000
    Assignee: Eli Lilly and Company
    Inventors: John A. Galloway, James A. Hoffmann
  • Glucagon-like insulinotropic peptides, compositions and methods
    Patent number: 5977071
    Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.
    Type: Grant
    Filed: September 10, 1997
    Date of Patent: November 2, 1999
    Assignee: Eli Lilly and Company
    Inventors: John A. Galloway, James A. Hoffmann
  • Glucagon-like insulinotropic peptides, compositions and methods
    Patent number: 5705483
    Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.
    Type: Grant
    Filed: March 21, 1995
    Date of Patent: January 6, 1998
    Assignee: Eli Lilly and Company
    Inventors: John A. Galloway, James A. Hoffmann
  • Human proinsulin pharmaceutical formulations
    Patent number: 4654324
    Abstract: A pharmaceutical composition which comprises human proinsulin in association with a pharmaceutically acceptable carrier is useful in controlling a diabetic condition and in promoting attainment of natural hormonal homeostasis, thereby preventing or substantially diminishing or retarding diabetic complications.
    Type: Grant
    Filed: December 17, 1984
    Date of Patent: March 31, 1987
    Assignee: Eli Lilly and Company
    Inventors: Ronald E. Chance, Bruce H. Frank, John A. Galloway
  • Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
    Patent number: 4652548
    Abstract: A pharmaceutical composition which comprises, in association with a pharmaceutically acceptable carrier, human insulin, human C-peptide, and human proinsulin, said human C-peptide being present in a molar ratio, human insulin to human C-peptide, of from about 1:4 to about 4:1, and said human proinsulin being present in a weight ratio, human insulin to human proinsulin, of from about 1:100 to about 100:1, is useful in treating diabetics and in promoting attainment of natural hormonal homeostasis, thereby preventing or substantially diminishing or retarding diabetic complications.
    Type: Grant
    Filed: December 17, 1984
    Date of Patent: March 24, 1987
    Assignee: Eli Lilly and Company
    Inventors: Ronald E. Chance, Bruce H. Frank, John A. Galloway
  • Pharmaceutical formulations comprising human insulin and human proinsulin
    Patent number: 4652547
    Abstract: A pharmaceutical composition which comprises, in association with a pharmaceutically acceptable carrier, human insulin and human proinsulin in a weight ratio, human insulin to human proinsulin, of from about 1:100 to about 100:1, is useful in treating diabetics and in promoting attainment of natural hormonal homeostasis, thereby preventing or substantially diminishing or retarding diabetic complications.
    Type: Grant
    Filed: December 17, 1984
    Date of Patent: March 24, 1987
    Assignee: Eli Lilly and Company
    Inventors: Ronald E. Chance, Bruce H. Frank, John A. Galloway